Relay Therapeutics Inc (NASDAQ: RLAY) started the day on Wednesday, with a price increase of 0.81% at $2.49, before settling in for the price of $2.47 at the close. Taking a more long-term approach, RLAY posted a 52-week range of $2.38-$10.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 307.65%. Meanwhile, its Annual Earning per share during the time was -23.05%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.14%. This publicly-traded company’s shares outstanding now amounts to $167.76 million, simultaneously with a float of $127.70 million. The organization now has a market capitalization sitting at $422.11 million. At the time of writing, stock’s 50-day Moving Average stood at $3.73, while the 200-day Moving Average is $5.67.
Relay Therapeutics Inc (RLAY) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Relay Therapeutics Inc’s current insider ownership accounts for 24.67%, in contrast to 80.03% institutional ownership. According to the most recent insider trade that took place on Mar 27 ’25, this organization’s President, R&D sold 986 shares at the rate of 2.84, making the entire transaction reach 2,800 in total value, affecting insider ownership by 615,052. Preceding that transaction, on Mar 27 ’25, Company’s insider sold 247 for 2.84, making the whole transaction’s value amount to 701. This particular insider is now the holder of 402,184 in total.
Relay Therapeutics Inc (RLAY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
Relay Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 6.14% and is forecasted to reach -2.34 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 0.41% through the next 5 years, which can be compared against the -23.05% growth it accomplished over the previous five years trading on the market.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Let’s observe the current performance indicators for Relay Therapeutics Inc (RLAY). It’s Quick Ratio in the last reported quarter now stands at 15.95. The Stock has managed to achieve an average true range (ATR) of 0.27. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 42.17.
In the same vein, RLAY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.40, a figure that is expected to reach -0.52 in the next quarter, and analysts are predicting that it will be -2.34 at the market close of one year from today.
Technical Analysis of Relay Therapeutics Inc (RLAY)
If we take a close look at the recent performances of Relay Therapeutics Inc (NASDAQ: RLAY), its last 5-days Average volume was 2.55 million that shows progress from its year to date volume of 2.36 million. During the previous 9 days, stock’s Stochastic %D was recorded 14.66% While, its Average True Range was 0.25.
Raw Stochastic average of Relay Therapeutics Inc (RLAY) in the period of the previous 100 days is set at 3.14%, which indicates a major fall in contrast to 10.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 69.35% that was lower than 77.69% volatility it exhibited in the past 100-days period.
